Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Change in Cash (2018 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Change in Cash for 8 consecutive years, with $30.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Cash rose 161.08% year-over-year to $30.4 million, compared with a TTM value of -$27.8 million through Sep 2025, up 19.3%, and an annual FY2024 reading of -$43.8 million, down 92.16% over the prior year.
  • Change in Cash was $30.4 million for Q3 2025 at X4 Pharmaceuticals, up from -$1.0 million in the prior quarter.
  • Across five years, Change in Cash topped out at $86.7 million in Q2 2024 and bottomed at -$49.8 million in Q3 2024.
  • Average Change in Cash over 5 years is -$540368.4, with a median of -$15.4 million recorded in 2022.
  • The sharpest move saw Change in Cash surged 677.28% in 2022, then plummeted 926.3% in 2024.
  • Year by year, Change in Cash stood at $5.4 million in 2021, then soared by 677.28% to $41.9 million in 2022, then plummeted by 177.26% to -$32.4 million in 2023, then fell by 28.96% to -$41.7 million in 2024, then skyrocketed by 172.89% to $30.4 million in 2025.
  • Business Quant data shows Change in Cash for XFOR at $30.4 million in Q3 2025, -$1.0 million in Q2 2025, and -$15.4 million in Q1 2025.